Invasive Aspergillosis

Invasive aspergillosis is a severe infection caused by the mould Aspergillus, most often A. fumigatus. It typically starts in the lungs and can spread rapidly to the sinuses, brain, or other organs. The condition almost exclusively affects people with significantly weakened immune systems, including those undergoing chemotherapy, organ transplant recipients, or patients on high-dose corticosteroids.

Medicine used to treat Invasive Aspergillosis

Vfend

Voriconazole

200mg

Developed to target serious fungal infections, this medication is indicated to address invasive aspergillosis and is utilized in systemic treatment protocols.

From $31.20 / tablet View

Who is at risk and how it develops

In healthy people, inhaled Aspergillus spores are cleared without causing disease. In immunocompromised individuals, the spores germinate and invade lung tissue. Symptoms often resemble a chest infection that does not respond to antibiotics: persistent fever, cough, chest pain, and occasionally coughing up blood. As infection spreads, confusion or focal neurological signs may appear.

Tropical and subtropical climates across South and Southeast Asia, including India, Thailand, and Indonesia, can have high environmental mould loads, which matters for transplant units and haematology wards managing high-risk patients.

Treatment

Invasive aspergillosis requires prompt antifungal therapy. Voriconazole is the established first-line agent and belongs to the broader class of antifungals. Treatment typically continues for weeks to months, guided by imaging and clinical response.

If symptoms suggesting invasive fungal infection develop in an immunocompromised patient, urgent medical assessment is needed.